Melanoma

Although melanoma represents a limited number of cutaneous cancers each year, it remains a significant public health crisis because the metastatic disease is associated with poor survival. The incidence of the disease has increased 200% since 1973 and the median age at diagnosis is 40 years, making...

Full description

Saved in:
Bibliographic Details
Other Authors: Lasfar, Ahmed (Editor), Cohen-Solal, Karine (Editor)
Format: Book Chapter
Published: IntechOpen 2021
Subjects:
Online Access:Get Fullteks
DOAB: description of the publication
Tags: Add Tag
No Tags, Be the first to tag this record!
LEADER 02527naaaa2200313uu 4500
001 doab_20_500_12854_77486
005 20220121
020 |a intechopen.91524 
020 |a 9781838808792 
020 |a 9781838808785 
020 |a 9781838808808 
024 7 |a 10.5772/intechopen.91524  |c doi 
041 0 |a English 
042 |a dc 
072 7 |a MJCL  |2 bicssc 
100 1 |a Lasfar, Ahmed  |4 edt 
700 1 |a Cohen-Solal, Karine  |4 edt 
700 1 |a Lasfar, Ahmed  |4 oth 
700 1 |a Cohen-Solal, Karine  |4 oth 
245 1 0 |a Melanoma 
260 |b IntechOpen  |c 2021 
300 |a 1 electronic resource (148 p.) 
506 0 |a Open Access  |2 star  |f Unrestricted online access 
520 |a Although melanoma represents a limited number of cutaneous cancers each year, it remains a significant public health crisis because the metastatic disease is associated with poor survival. The incidence of the disease has increased 200% since 1973 and the median age at diagnosis is 40 years, making it one of the most significant cancers responsible for productive years of life lost. Fortunately, there has been unprecedented progress in the treatment of advanced melanoma, largely through advances in understanding how to manipulate immune responses and target selective genetic mutations in melanoma patients. Clinical benefits to patients with advanced melanoma have been nevertheless limited by the development of innate and acquired drug resistance, and numerous efforts are focusing on the elucidation of these mechanisms. Combination strategies are being actively investigated to overcome drug resistance, by awakening existing anti-tumor mechanisms disabled by a cancer-promoting microenvironment. This book explores the advances and challenges associated with melanoma today, particularly those related to its diagnosis and management. It also proposes new avenues for therapeutic opportunities based on sustained research efforts and ever-growing technological advances. This is a relevant source of knowledge, very useful for researchers, medical doctors, health providers and all individuals interested in learning more about this devastating disease. 
540 |a Creative Commons  |f https://creativecommons.org/licenses/by/3.0/  |2 cc  |4 https://creativecommons.org/licenses/by/3.0/ 
546 |a English 
650 7 |a Oncology  |2 bicssc 
856 4 0 |a www.oapen.org  |u https://www.intechopen.com/books/10338  |7 0  |z Get Fullteks 
856 4 0 |a www.oapen.org  |u https://directory.doabooks.org/handle/20.500.12854/77486  |7 0  |z DOAB: description of the publication